| 词条 | Fontolizumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 457119389 | type = mab | mab_type = mab | source = zu/o | target = interferon gamma | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 326859-36-3 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 6J92H2439Z | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D04242 | chemical_formula = | molecular_weight = ca. 150 kg/mol }}Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3] References1. ^Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association. {{Immunosuppressants}}{{Monoclonals for immune system}}{{Cytokine receptor modulators}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^{{cite journal|pmid=19637334|year=2009|last1=Reinisch|first1=W|last2=De Villiers|first2=W|last3=Bene|first3=L|last4=Simon|first4=L|last5=Rácz|first5=I|last6=Katz|first6=S|last7=Altorjay|first7=I|last8=Feagan|first8=B|last9=Riff|first9=D|last10=Bernstein|first10=Charles N.|last11=Hommes|first11=Daniel|last12=Rutgeerts|first12=Paul|last13=Cortot|first13=Antoine|last14=Gaspari|first14=Michael|last15=Cheng|first15=May|last16=Pearce|first16=Tillman|last17=Sands|first17=Bruce E.|title=Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study|doi=10.1002/ibd.21038|journal=Inflammatory Bowel Diseases|pages=233–42|volume=16|issue=2|display-authors=8}} 3. ^{{ClinicalTrialsGov|NCT00281294|A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis}} 2 : Monoclonal antibodies|Abandoned drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。